These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38569825)

  • 1. CHIEF Effects of Sodium Glucose Co-Transporter Inhibitors on Health-Related Quality of Life in Heart Failure.
    Allen LA
    JACC Heart Fail; 2024 Apr; 12(4):719-721. PubMed ID: 38569825
    [No Abstract]   [Full Text] [Related]  

  • 2. Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future.
    Nana M; Morgan H; Bondugulapati LNR
    Heart Fail Rev; 2021 Jul; 26(4):953-960. PubMed ID: 32020487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology.
    Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; de Boer RA; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund L; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
    Eur J Heart Fail; 2020 Sep; 22(9):1495-1503. PubMed ID: 32618086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [ANMCO Position paper: Sodium-glucose co-transporter 2 inhibitors for the prevention of heart failure in diabetic patients and for the treatment of heart failure patients with and without diabetes].
    Gronda E; Napoli C; Iacoviello M; Urbinati S; Caldarola P; Mannucci E; Colivicchi F; Gabrielli D
    G Ital Cardiol (Rome); 2021 Aug; 22(8):675-687. PubMed ID: 34310573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations.
    Butler J; Anker SD; Filippatos G; Usman MS; Ferreira JP; Zannad F; Packer M
    Eur Heart J; 2021 Dec; 42(48):4887-4890. PubMed ID: 34718518
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of heart failure: the dawn of the era of sodium-glucose co-transporter-2 inhibitors.
    Crea F
    Eur Heart J; 2020 Sep; 41(36):3379-3383. PubMed ID: 33216881
    [No Abstract]   [Full Text] [Related]  

  • 7. Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure.
    Liang B; Gu N
    Cardiovasc Diabetol; 2022 May; 21(1):84. PubMed ID: 35624512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF.
    Bocchi EA; Biolo A; Moura LZ; Figueiredo Neto JA; Montenegro CEL; Albuquerque DC
    Arq Bras Cardiol; 2021 Feb; 116(2):355-358. PubMed ID: 33656089
    [No Abstract]   [Full Text] [Related]  

  • 9. Beyond the myocardium: Sodium-glucose co-transporter-2 inhibitors in heart failure.
    Chilton RJ
    Diabetes Obes Metab; 2021 May; 23(5):1215-1218. PubMed ID: 33464709
    [No Abstract]   [Full Text] [Related]  

  • 10. Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
    Tsampasian V; Elghazaly H; Chattopadhyay R; Ali O; Corballis N; Chousou PA; Clark A; Garg P; Vassiliou VS
    Eur J Prev Cardiol; 2022 May; 29(6):e227-e229. PubMed ID: 34850881
    [No Abstract]   [Full Text] [Related]  

  • 11. Meta-Analysis Evaluating the Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Acute or Recently Decompensated Heart Failure.
    Patoulias D; Doumas M; Kassimis G; Fragakis N; Papadopoulos C
    Am J Cardiol; 2022 Jun; 172():171-172. PubMed ID: 35396145
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of sodium-glucose co-transporter 2 protein inhibitors in heart failure: more than an antidiabetic drug?
    Savarimuthu S; Harky A
    Expert Opin Pharmacother; 2022 Feb; 23(3):377-386. PubMed ID: 34713764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials.
    Liang B; Gu N
    Int J Med Sci; 2022; 19(7):1118-1121. PubMed ID: 35919809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure.
    Greene SJ; Butler J; Kosiborod MN
    Am J Med; 2024 Feb; 137(2S):S25-S34. PubMed ID: 38184323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology Focus: Clinical Evidence for the Use of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction.
    Berendse J; Newenhouse L
    S D Med; 2022 Jul; 75(7):328-329. PubMed ID: 36542574
    [No Abstract]   [Full Text] [Related]  

  • 16. Empagliflozin for Patients with Heart Failure and Type 2 Diabetes Mellitus: Clinical Evidence in Comparison with Other Sodium-Glucose Co-transporter-2 Inhibitors and Potential Mechanism.
    Liang B; Li R; Zhang P; Gu N
    J Cardiovasc Transl Res; 2023 Apr; 16(2):327-340. PubMed ID: 35969357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of sodium glucose co-transporter 2 inhibitors in acute heart failure: a practical guidance.
    Ferreira JP; Pimenta J; Moura B; Aguiar C; Franco F
    ESC Heart Fail; 2022 Dec; 9(6):4344-4347. PubMed ID: 36004699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial'.
    Kokhan E; Kiyakbaev G; Medovchshikov V
    Eur J Heart Fail; 2022 Jul; 24(7):1323-1324. PubMed ID: 35238461
    [No Abstract]   [Full Text] [Related]  

  • 19. Potential roles of sodium-glucose co-transporter 2 inhibitors in attenuating cardiac arrhythmias in diabetes and heart failure.
    Attachaipanich T; Chattipakorn SC; Chattipakorn N
    J Cell Physiol; 2022 May; 237(5):2404-2419. PubMed ID: 35324001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comment on Sodium-Glucose Co-Transporter 2 Inhibitors and Heart Failure.
    Cure E; Cumhur Cure M
    Am J Cardiol; 2020 May; 125(10):1602. PubMed ID: 32241553
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.